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Background and aims: Thiopurines, including 6-mercaptopurine (6-MP) and azathioprine 
(AZA), are the mainstay of maintenance therapy for Crohn’s disease (CD). However, studies 
examining their effectiveness in routine practice among diverse patient populations are lacking. 
Among a cohort of new users of 6MP/AZA, we described treatment patterns and changes in 
subsequent therapy.
Methods: Using the Truven Health Analytics databases, we identified all individuals diagnosed 
with CD and initiating 6-MP/AZA monotherapy from 2001–2008 (n=3,657). We estimated the 
proportion of CD patients remaining on 6-MP/AZA monotherapy, using Kaplan–Meier methods, 
and identified predictors of treatment noncontinuation, using multivariable Cox regression. Among 
the “noncontinuers,” we described subsequent patterns of maintenance therapy and summarized the 
diagnosis and procedure codes and prescription drug claims preceding treatment discontinuation.
Results: The 1-year 6-MP/AZA treatment continuation rate was 42%. Children (age #18 years) 
and individuals with no prior anti-tumor necrosis factor (TNF) use were more likely to continue 
6-MP/AZA, while those dispensed more (.4) outpatient prescriptions for any drug before initia-
tion of 6-MP/AZA were less likely to continue maintenance treatment. Overall, 1,128 (39%) and
105 (4%) individuals experienced a clinical event potentially indicating active disease or 6-MP/
AZA-intolerance prior to discontinuation, respectively. Most patients discontinued therapy; among
the remaining patients who failed to continue 6-MP/AZA, most augmented with an anti-TNF.
Conclusion: Most patients initiating 6-MP/AZA monotherapy did not continue beyond 1 year.
In contrast to trial evidence showing 1-year remission rates of 40%–80%, this study observed
a lower effectiveness of 6-MP/AZA treatment, possibly due to differences in disease severity,
patient demographics, comorbidity, adherence, and health care utilization.
Keywords: immunomodulators, outcomes research/measurement, inflammatory bowel disease,
patterns of care
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting close 
to 500,000 Americans.1,2 CD is characterized by flares of abdominal pain, diarrhea, 
rectal bleeding, and extraintestinal manifestations, followed by periods of remission. 
Because the disease is typically relapsing and remitting, the two goals of medical 
therapy are to treat disease flares and prolong remission.
Since the initial trial conducted by Present et al in 1980 describing the efficacy 
of 6-mercaptopurine in (6-MP) in the treatment of CD, thiopurines, including 6-MP 
and azathioprine (AZA), have become mainstays in the IBD therapeutic arsenal.3–5 
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 Subsequent randomized controlled trials (RCTs) have 
reported 1-year remission rates for 6-MP/AZA in adult 
CD populations of 40%–70%;6–9 and a single RCT in pedi-
atric CD demonstrated a .80% remission rate at 12 and 
18 months.10 Consequently, a recent meta-analysis from 
the Cochrane Collaboration concluded that thiopurines are 
effective for inducing and maintaining remission among 
adult CD patients.4
In addition to RCTs, which are the gold standard for evaluat-
ing treatment efficacy, clinical effectiveness research involves 
the study of the benefits and harms of medications when used 
in “real-world” settings, in which patients tend to be older, 
have more comorbidity,11 are not as carefully monitored or 
adherent to their medications, and remain on treatment longer 
than subjects in RCTs.12 An early study by Fraser et al13 using 
30 years of data from an IBD clinic in Oxford, England reported 
overall rates of remission in CD patients initiating AZA of 45% 
(123/272), consistent with, though on the low end of, RCT 
findings. However, data from more recent studies examining the 
real world use of 6-MP/AZA have suggested that the clinical 
effectiveness of thiopurines in practice may be less than the effi-
cacy demonstrated in clinical trials. A study by Goodhand et al14 
reported that 6-month steroid-free remission was achieved 
in only 30% (15/50) of children and 38% (19/50) of adults 
treated with thiopurines. Another study, by Riello et al,15 found 
similar rates of steroid-free remission in a small, single-center 
observational pediatric cohort of CD patients. Most recently, 
an observational study by Hyams et al16 reported that children 
who initiated immunomodulator treatment had similar rates of 
remission at 1 year when compared with children who did not 
initiate immunomodulator or anti-tumor necrosis factor (TNF) 
treatment, indicating a lack of effectiveness.
To further evaluate the clinical effectiveness of thiopurines 
in a large and diverse population, we used health insurance 
claims data in the USA to undertake a retrospective cohort 
study of individuals diagnosed with CD who initiated 6-MP/
AZA monotherapy. Specifically, we estimated the proportion 
of CD patients that remained on this maintenance regimen 
over time and identified independent patient-level predic-
tors of 6-MP/AZA monotherapy noncontinuation. We also 
described clinical events occurring before discontinuation, 
and examined the subsequent treatment strategies utilized.
Materials and methods
Data source
The data for this study were drawn from Truven Health 
Analytics databases (Ann Arbor, MI, USA), including the 
Commercial Claims and Encounters database (January 1, 
2000 – December 31, 2009) and the Medicare Supple-
mental and Coordination of Benefits database (January 1, 
2006 – December 31, 2009), collectively referred to as “the 
databases.” The databases capture person-specific clinical 
utilization, expenditures, and enrollment information across 
inpatient, outpatient, prescription drug, and carve-out ser-
vices from a selection of large employers, health plans, and 
government and public organizations in the USA. The paid 
claims and encounter data for the study period were linked 
to detailed patient information across sites and types of pro-
viders, and over time. The annual medical databases include 
commercial health data from approximately 100 payers.
Inpatient and outpatient diagnoses and procedures were 
recorded using International Classification of Diseases, ninth 
revision (ICD-9 CM) codes, Common Procedural Termi-
nology (CPT) codes, and Healthcare Common Procedure 
Coding System (HCPCS) codes. Drug information, includ-
ing administration and the dispensing of specific treatments, 
were identified using HCPCS codes and National Drug Codes 
(NDCs).17 Patient demographic data, and start and stop dates 
for plan enrollments were recorded. As all records used in 
the analysis were previously collected and deidentified, this 
study did not constitute human subjects research.
study sample
All individuals with a first prescription claim for 6-MP/AZA 
between January 1, 2001 and December 31, 2008 were eligible 
for study inclusion. The date of the first 6-MP/AZA prescrip-
tion claim was defined as the “index prescription date.” Each 
individual was required to have plan enrollment for at least 
12 - months prior to (“preindex period”) and following (“postin-
dex period”) the index prescription date, creating a cohort of 
incident users of 6-MP/AZA with sufficient health care utili-
zation information to assess the important predictors and out-
comes of interest.18 To ensure that the study population included 
only CD patients, individuals were only included if they had 
at least two claims for CD (ICD-9: 555) on different days and 
no claims for ulcerative colitis (UC) (ICD-9: 556) during the 
preindex period. To ensure a study population in which 6-MP/
AZA monotherapy was the primary maintenance strategy, all 
individuals who used other CD treatment (ie, methotrexate, an 
anti-TNF agent, or natalizumab) during the 90-day “washout 
period” prior to the index prescription date were excluded.
Outcome definitions
Treatment continuation
Because administrative data lack the detail necessary 
to identify all clinically relevant outcomes, including 
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disease exacerbations, changes in disease activity, and 
medication-related toxicity, the primary outcome for this 
study, determined a priori, was the continuation of 6-MP/
AZA as the primary treatment strategy. This is an appropri-
ate proxy outcome for clinical effectiveness because patients 
who discontinue 6-MP/AZA, who augment their treatment 
with another agent, or who switch agents are likely either 
intolerant to or “failures of 6-MP/AZA.” Treatment continu-
ation was defined as continuous 6-MP/AZA monotherapy 
(without concurrent use of other CD maintenance treatment, 
such as methotrexate, anti-TNF agents, or natalizumab). The 
period of use was determined by the date of 6-MP/AZA 
dispensing, plus days supplied, plus an additional 90-day 
“grace” period to account for delays in prescription dispens-
ing or poor adherence. If the number of days supplied was 
missing, it was assumed to be 30 days.
Treatment augmentation, switch, and discontinuation
Three mutually exclusive secondary outcomes were defined, 
which together accounted for the failure of treatment con-
tinuation (Figure 1). The first category was a “treatment 
augmentation,” defined as the presence of a claim for 
methotrexate, an anti-TNF agent, or natalizumab (a “new 
maintenance treatment”) occurring alongside continuous 
6-MP/AZA treatment, allowing for a 90-day grace period. 
The date of augmentation was defined as the date of the first 
new maintenance treatment claim. The second category was 
a “treatment switch,” defined as the presence of a claim for a 
new maintenance treatment in addition to the lack of a claim 
for 6-MP/AZA during the period from the date of the new 
maintenance treatment plus the number of days supplied and 
a 90-day grace period. The date of switch was the date of the 
first new maintenance treatment claim. The third outcome 
was a “treatment discontinuation,” defined as the lack of a 
claim for any maintenance treatment (ie, 6-MP/AZA or a new 
maintenance treatment) during the period from the date of 
last prescription claim for 6-MP/AZA plus the days supplied 
and a 90-day grace period. The date of discontinuation was 
the date of the last 6-MP/AZA claim plus the days supplied. 
All remaining individuals were considered to be censored 
either at disenrollment from the health plan or at the end of 




























































1.  Two CD claims on different days in the 12 months before initiation
2.  Assess predictors of interest
3.  Exclude individuals with prior methotrexate, anti-TNF, or
     natalizumab in the 90 days before initiation
Figure 1 illustration of the cohort of CD patients who initiated 6-mercaptopurine/azathioprine, and the three secondary outcomes of treatment, discontinuation, 
augmentation, and switch.
Abbreviations: 6-MP, 6-mercaptopurine; aZa, azathioprine; CD, Crohn’s disease; TnF, tumor necrosis factor.
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Data on patient characteristics that were hypothesized to 
be independently associated with failure to continue 6-MP/
AZA treatment were obtained from the inpatient, outpatient, 
and pharmacy claims during the 12-month preindex period. 
The demographic information included age (at the index 
prescription date), sex, and region of residence (Northeast, 
North Central, South, and West). Treatment-related variables 
included the year of 6-MP/AZA initiation and prior corticoster-
oid, 5-aminosalicylate (5-ASA), and antibiotic use during the 
preindex period. Prior methotrexate, anti-TNF, and natalizumab 
use was assessed during the 9 months prior to the 90-day wash-
out period. Other measures, of comorbid illness and health care 
utilization, measured during the preindex period included the 
Charlson comorbidity score (0, 1, $2),19 a prior diagnosis of 
rheumatologic disease or other autoimmune disease (includ-
ing rheumatoid arthritis, ankylosing spondylitis, psoriatic 
arthritis, plaque psoriasis, juvenile idiopathic arthritis, and 
multiple sclerosis), the number of unique outpatient visits, the 
number of unique outpatient gastrointestinal visits, the number 
of unique generic drug prescriptions (a marker of health care 
utilization), the number of unique gastrointestinal procedures, 
and the number of unique hospitalizations (occurring at least 
2 days apart) with a CD discharge diagnosis.
Clinical events occurring prior  
to study outcomes
In an exploratory analysis, we summarized the diagnosis 
codes and procedure and outpatient pharmaceutical claims 
occurring prior to the study outcomes. We defined two broad 
categories of events that might indicate intolerance to the 
initial 6-MP/AZA treatment or active disease. “Possible 
indicators of intolerance” included a diagnosis of pancreatitis, 
liver toxicity, or low white blood cell count during the 60-day 
period prior to reaching any of the above study endpoints (aug-
mentation, switch, or discontinuation). “Possible indicators 
of active disease” included a prescription for an oral steroid, 
a gastrointestinal surgical procedure, or a hospitalization with 
a primary discharge diagnosis of CD within the 60 days prior 
to any of the above endpoints. The period of 60 days was 
selected based on clinical input. All the ICD-9 diagnosis and 
procedure codes, NDCs, and HCPCS codes used to define the 
study outcomes are listed online (Tables S1 and S2).
statistical analysis
We utilized nonparametric Kaplan–Meier survival analysis 
to estimate the time-to-event (failure to continue 6-MP/AZA 
monotherapy) among the cohort of CD patients initiating 
6-MP/AZA between January 1, 2001 and December 31, 
2008. Descriptive statistics were generated to report the mean 
and interquartile range of the time-to-treatment failure. We 
estimated the 1-year event-free rate, defined as the proportion 
of the cohort remaining on their initial continuous 6-MP/
AZA therapy at 1-year postinitiation and reported this for 
the cohort overall and stratified by children (#18 years) and 
adult (>18 years) populations. We performed multivariable 
Cox proportional hazards regression to identify patient-level 
predictors that were independently associated with failure 
to continue 6-MP/AZA. Our models estimated unadjusted 
and adjusted hazard ratios (HRs) (controlling for all other 
predictors) and 95% confidence intervals (CIs) for all the 
predictors of interest. As 8–16 weeks of 6-MP/AZA treatment 
are required in order to obtain pharmacokinetic effects, we 
conducted a subanalysis examining the effectiveness of initial 
6-MP/AZA treatment among the CD patients remaining on 
monotherapy for at least 3 months.
For individuals failing to continue 6-MP/AZA mono-
therapy, we reported the number and proportion of individu-
als who started on alternative treatment strategies. Finally, 
we summarized the number and proportion of diagnosis and 
procedure codes and outpatient prescription drug claims for the 
clinical events occurring 60 days prior to the failure of treat-
ment continuation that possibly indicated either 6-MP/AZA 
treatment intolerance or active CD. All the statistical analyses 
were conducted using SAS version 9.2 (Cary, NC, USA).
Results
study population
The study sample comprised 3,657 individuals with a diag-
nosis of CD initiating 6-MP/AZA therapy from January 1, 
2001– December 31, 2008, with a median follow up of 2.5 
years (interquartile range 1.6, 4.0). Table 1 reports the demo-
graphic and clinical characteristics of the cohort. Children 
(aged 0– 18 years) accounted for 16% of the study sample, 
while those aged 60 years and older made up approximately 
11%. The majority of the individuals in the cohort were 
women (54%) and most frequently lived in the South (40%). 
Prior to 6-MP/AZA initiation, the use of methotrexate (<1%) 
and anti-TNFs (2%) was rare; however, the majority of indi-
viduals in the cohort used corticosteroids (59%), 5-ASAs 
(72%), and antibiotics (64%).
rates and predictors of treatment 
noncontinuation
Figure 2 illustrates the nonparametric Kaplan–Meier curve 
estimating the time-to-noncontinuation among the cohort of 
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CD initiators of 6-MP/AZA over time (measured in months 
from initiation). Nearly one-quarter of individuals in the 
cohort did not continue 6-MP/AZA monotherapy longer than 
2 months. Similarly, more than 50% and 75% of individuals 
in the cohort failed to continue 6-MP/AZA treatment for 
8 months and 28 months, respectively. The overall 1-year 
continuation rate of 6-MP/AZA monotherapy was 42%. 
Stratified by age group, the 1-year continuation rate was 54% 
for children (#18 years) and 41% for adults (>18 years). For 
individuals with prior anti-TNF use, the 1-year continuation 
rate was 22%. Among the individuals who continued on 
6-MP/AZA treatment for 3 or more months, the continuation 
rate at 12, 18, and 24 months was 63%, 50%, and 42%, 
respectively. The median follow up among CD patients after 
failure to continue 6-MP/AZA was 2.03 years (interquartile 
range 1.20–3.42).
We estimated unadjusted and adjusted HRs (aHRs) and 
95% CIs for the association between each patient-level pre-
dictor of interest and initial 6-MP/AZA treatment failure 
(Table 2), using multivariable Cox proportional hazards 
regression. The individuals who used anti-TNFs prior to 
their initial 6-MP/AZA prescription were more likely to fail 
to continue on treatment compared with those who did not 
(aHR =1.64, 95% CI: 1.26, 2.13). Age appeared to have a 
nonlinear association with noncontinuation, where individu-
als aged 19–29, 30–39, and 40–49 years all had an elevated 
hazard compared with individuals aged 0–18 years, while 
older adults aged 50–59 and $60 years did not. When 
age was dichotomized (age #18 vs >18 years), adults were 
more likely than children to fail to continue on 6-MP/AZA 
(aHR =0.85, 95% CI: 0.76, 0.95). Having a diagnosis of a 
rheumatologic or other autoimmune disease with an indica-
tion for an anti-TNF prior to 6-MP initiation increased the 
hazard of treatment noncontinuation (aHR =1.23, 95% CI: 
1.00, 1.51). Lastly, individuals receiving a higher number of 
unique generic prescription drug fills in the year prior to their 
6-MP/AZA initiation (5–8, 9–12, and $13 vs 1–4 unique 
generic prescriptions) were more likely to fail to continue 
6-MP/AZA monotherapy.
subsequent maintenance therapy  
strategy changes
Table 3 reports the number and proportion of the 2,845 indi-
viduals who did not continue on 6-MP/AZA monotherapy 
and who changed to another maintenance therapy strategy. 
A total of 484 individuals (17%) augmented their 6-MP/AZA 
treatment with an anti-TNF agent. Almost 9% discontinued 
6-MP/AZA and switched to another CD strategy, such as 
methotrexate alone (1.6%), an anti-TNF alone (7%), or an 
anti-TNF in combination with methotrexate (,1%). Most CD 
patients (n=2,108 or 74%) completely discontinued 6-MP/
AZA without augmenting or switching.
Possible indicators of 6-MP/aZa 
intolerance or active disease
Among individuals who did not continue on 6-MP/AZA 
monotherapy (n=2,845), Table 4 reports the number and 
proportion of patients who received a diagnosis, procedure, 
or prescription for clinical events, which could indicate a 
Table 1 Characteristics of 3,657 Crohn’s disease patients 
initiating 6-MP/aZa from 2001–2008






age (mean, sD) 42 (16.77)
 0 to 18 575 15.7%
 19 to 29 537 14.7%
 30 to 39 618 16.9%
 40 to 49 719 19.7%
 50 to 59 809 22.1%
 $60 399 10.9%
regiona
 northeast 443 12.1%
 north Central 1,167 31.9%
 south 1,463 40.0%
 West 574 15.7%
Prior drug useb
 Methotrexate 17 0.5%
 anti-TnFs 68 1.9%
Concomitant drug usec
 Corticosteroids 2,149 58.8%
 5-asas 2,637 72.1%
 antibiotics 2,333 63.8%
Measures of comorbidity
 Charlson score, 0 2,903 79.4%
 Charlson score, 1 484 13.2%
 Charlson score, $2 270 7.4%
 Prior rheumatologic condition 120 3.3%
number of gi outpatient visits
 0 visits 1,128 30.8%
 1 to 2 visits 871 23.8%
 $3 visits 1,658 45.3%
number of distinct generic drug prescriptions
 1 to 4 523 14.3%
 5 to 8 1,153 31.5%
 9 to 12 973 26.6%
 $13 1,008 27.6%
Notes: aregion was missing for ten individuals; bprior use was defined as occurring 
during the 3-12 months prior to 6-MP/aZa initiation; cconcomitant use was defined 
as occurring during the 12 months prior to 6-MP/aZa initiation.
Abbreviations: 5-asa, 5-aminosalicylate; 6-MP, 6-mercaptopurine; aZa, 
azathioprine; gi, gastrointestinal; sD, standard deviation; TnF, tumor necrosis factor.
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possible intolerance to 6-MP/AZA or active disease flare. 
Overall, 105 individuals (4%) received diagnoses that could 
indicate a possible intolerance, including a diagnosis for pan-
creatitis (2%), liver toxicity (1%), and low white blood cell 
count (1%). Similarly, 1,128 individuals received diagnoses, 
procedures, or prescriptions for clinical events that could 
indicate an active disease flare (39%), including a prescrip-
tion for an oral steroid (27%), a gastrointestinal-related proce-
dure (16%), and hospitalization with a CD-related discharge 
diagnosis (8%). Almost 2% of the cohort experienced both 
indicators during the study period.
Discussion
An examination of the patterns and effectiveness of 6-MP/
AZA treatment for maintenance of CD remission is important 
because patients treated in the routine setting are different 























































Figure 2 Time-to-treatment noncontinuation of initial 6-MP/aZa maintenance therapy.
Notes: nonparametric Kaplan–Meier survival curves estimate the time-to-noncontinuation of initial 6-MP/aZa maintenance therapy among a cohort of CD patients 
(n=3,657) initiating 6-MP/aZa maintenance therapy between January 1, 2001 and December 31, 2008, overall (A) and stratified by age (#18 vs >18 years), (B). at 12, 24, 
and 36 months, the numbers of CD patients at risk were 1,544, 730, and 352. Stratified by age, the same numbers of patients at risk were 170, 67, and 32 and 1,374, 663, 
and 320 among those #18 years and >18, respectively.
Abbreviations: 6-MP, 6-mercaptopurine; aZa, azathioprine; CD, Crohn’s disease.
Table 2 Patient-level predictors of failure to continue initial 
6-MP/aZa among 3,657 Crohn’s disease patients




Female vs male 0.87 (0.81–0.93) 0.92 (0.85–0.99)
19–29 years vs 0–18 years 1.47 (1.28–1.68) 1.39 (1.21–1.59)
30–39 years vs 0–18 years 1.35 (1.19–1.54) 1.25 (1.09–1.43)
40–49 years vs 0–18 years 1.27 (1.12–1.43) 1.16 (1.02–1.32)
50–59 years vs 0–18 years 1.17 (1.03–1.32) 1.04 (0.91–1.19)
$60 years vs 0–18 years 1.20 (1.04–1.40) 1.07 (0.91–1.25)
northeast vs south 0.81 (0.72–0.92) 0.86 (0.76–0.97)
north Central vs south 0.90 (0.82–0.98) 0.91 (0.84–1.00)
West vs south 0.93 (0.83–1.03) 0.95 (0.85–1.07)
anti-TnF prescription prior  
to initiationa (yes vs no)
1.81 (1.40–2.33) 1.64 (1.26–2.13)
Methotrexate prescription  
prior to initiationa (yes vs no)
1.35 (0.82–2.25) 1.21 (0.73–2.03)
salicylate prescription prior  
to initiationb (yes vs no)
0.96 (0.88–1.04) 0.94 (0.86–1.02)
steroid prescription prior  
to initiationb (yes vs no)
1.00 (0.93–1.08) 0.95 (0.88–1.03)
antibiotic prescription  
prior to initiation (yes vs no)
1.19 (1.10–1.28) 1.06 (0.96–1.16)
history of rheumatologic  
diseaseb (yes vs no)
1.27 (1.04–1.55) 1.23 (1.00–1.51)
5–8 vs 1–4 generic  
prescriptionsb
1.16 (1.03–1.31) 1.20 (1.05–1.37)
9–12 vs 1–4 generic  
prescriptionsb
1.24 (1.09–1.40) 1.28 (1.10–1.49)
$13 vs 1–4 generic  
prescriptionsb
1.43 (1.27–1.62) 1.46 (1.23–1.73)
Notes: aPrior use was defined as occurring during the 3-12 months prior to 6-MP/
aZa initiation; ball variables were assessed during the 12 months prior to 6-MP/
aZa initiation; call estimates were adjusted for all the variables above in addition to 
year of initiation, Charlson score, number of office visits, number of gastrointestinal 
procedures, and number of hospitalizations.
Abbreviations: 6-MP, 6-mercaptopurine; AZA, azathioprine; CI, confidence 
interval; hr, hazard ratio; TnF, tumor necrosis factor; vs, versus.
Table 3 Maintenance therapy changes among 2,845 patients 
diagnosed with Crohn’s disease who failed to continue initial 
6-MP/aZa therapy
Treatment strategy Number of patients (%)
Discontinued all therapy 2,108 (74.02)
switched to another therapy
 natalizumab 0 (0.00)
 Methotrexate 45 (1.58)
 anti-TnF 203 (7.13)
 anti-TnF + methotrexate 5 (0.18)
augmented with another therapy
 6-MP/aZa + anti-TnF 484 (16.99)
Abbreviations: 6-MP, 6-mercaptopurine; aZa, azathioprine; TnF, tumor necrosis 
factor.
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3,657 individuals with CD initiating on 6-MP/AZA (98% 
of whom were immunomodulator or biologic naïve), we 
found that approximately 42% of the CD patients who initi-
ated 6-MP/AZA monotherapy remained on this treatment 
strategy after 1 year, and only 28% remained at 2 years. 
When restricted to patients who remained on therapy for 
at least 3 months (an adequate amount of time to achieve 
pharmacokinetic effects), 63% and 42% remained on their 
6-MP/AZA without augmenting or switching at 1 and 
2 years, respectively. Taken together, these data suggest that 
most individuals benefit from 6-MP/AZA monotherapy at 
1 year; however, the longer-term benefits remain uncertain, 
and our data do not allow us to comment directly on these 
benefits. Despite this uncertainty, many clinical algorithms 
recommend this approach, and it has become a mainstay of 
medical therapy for moderate to severe CD.20,21
Because the primary outcome of our study, treatment 
continuation, is different than the clinical outcomes of disease 
remission or steroid-free remission used in clinical trials 
and retrospective chart reviews, direct comparisons with the 
existing literature are not possible. However, as treatment 
continuation may either over- or underestimate clinical 
remission, we believe that, on balance, it is a reasonable 
proxy indicator. Treatment continuation will overestimate 
remission in instances where patients remain on 6-MP/AZA 
despite active disease, or may underestimate clinical remis-
sion in instances where discontinuation occurs due to poor 
adherence or other reasons aside from treatment failures.
Our findings are in line with emerging evidence suggest-
ing that the real-world clinical effectiveness of 6-MP/AZA 
may be somewhat lower than the efficacy initially observed 
in randomized trials. The Cochrane Collaboration conducted 
a meta-analysis of eight published randomized, double-blind, 
placebo-controlled trials of AZA or 6-MP therapy in adult 
patients ($19 years) with CD4 and concluded that both 
treatments were effective in maintaining the remission of 
CD, with a summary odds ratio (OR) in the AZA trials of 
2.32 (95% CI: 1.55, 3.49) and in the 6-MP trials of 3.32 
(95% CI: 1.40, 7.87). The 1-year remission rates reported 
in these trials ranged from 40%–70%.6–9 The Markowitz 
et al pediatric study10 showed similar, if not higher, efficacy, 
with .80% of children in remission at 1 year. However, the 
success of 6-MP/AZA when used in clinical practice has not 
been consistently documented in the literature. The 30-year 
retrospective study by Fraser et al13 investigating 272 patients 
from an IBD referral center in Oxford, England reported the 
rate of overall remission (defined as being steroid-free for 
at least 3 months) was 45%, which increased to 64% among 
CD patients who completed 6 or more months of treatment. 
Two small observational studies have shown relatively low 
clinical effectiveness of 6-MP/AZA in pediatric CD in clini-
cal settings. Riello et al15 conducted a retrospective obser-
vational cohort study of AZA effectiveness in 105 pediatric 
CD patients from a single center in Paris, France. Remission 
(as measured by a pediatric CD activity index #10 without 
any steroid medication) at 12 months of follow up occurred 
in only 40% of patients. More recently, Hyams et al16 drew 
upon a multicenter, inception cohort to compare 1-year 
remission outcomes for initiators of anti-TNFs, initiators 
of immunomodulators, and children who did not initiate 
immunomodulator therapy. After propensity score match-
ing, the authors found no comparative benefit of initiating 
immunomodulators versus not receiving treatment (OR: 1.3, 
95% CI: 0.6, 2.8). Therefore, our findings in a larger and more 
diverse sample are consistent with this emerging literature 
regarding real-world clinical effectiveness.
One particularly notable finding from our study was the 
effects of age on length of treatment continuation. Children 
had longer periods of treatment continuation than did adults, 
which may indicate a higher response to 6-MP/AZA in the 
pediatric versus adult populations. Increased efficacy of 
6-MP/AZA in the pediatric population was suggested by the 
Markowitz study,10 where it was hypothesized that treatment 
earlier in the course of the disease may be a potential disease-
modifying strategy.22 Another possible explanation for the 
longer treatment continuation among children observed here 
is that children may experience less toxicity than adults, as 
has been suggested by a small, single-center retrospective 
study by Goodhand et al,14 which found that 6-MP/AZA 
was better tolerated in children than adults (albeit with no 
Table 4 Clinical events occurring among 2,845 CD patients 
during the 60 days prior to failure of initial 6-MP/aZa treatment 
continuation
Event of interest Number of patients 
 (%a)
Possible indicator of intolerance 105 (3.6)
 Pancreatitis diagnosis 71 (2.4)
 liver toxicity diagnosis 17 (0.6)
 low white blood cell count diagnosis 18 (0.6)
Possible indicator of active disease 1,128 (38.6)
 Oral steroid prescription 799 (27.4)
 gi surgery procedure 480 (16.4)
 hospitalization related to CD 246 (8.4)
Both 56 (1.9)
Notes: aindividuals can experience multiple events in each category, therefore the 
column percentages do not sum to 100%.
Abbreviations: 6-MP, 6-mercaptopurine; aZa, azathioprine; CD, Crohn’s disease; 
gi, gastrointestinal.
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difference in efficacy). Finally, nonmechanistic reasons may 
also explain the elevated continuation in children, where 
parents’ involvement in the management of their child’s 
disease may improve adherence. We also noted that individu-
als initiating 6-MP/AZA in older age ($50 years) were at 
a reduced hazard of treatment noncontinuation compared 
with other adults (19–49 years), consistent with the findings 
by Fraser et al.13 This may indicate that 6-MP/AZA is more 
effective in older individuals, or may reflect differences in 
disease course, adherence, and/or insurance coverage in the 
elderly in the USA.
An additional finding worth highlighting is that although 
prior anti-TNF users were less likely to continue on long-term 
6-MP/AZA monotherapy than were anti-TNF naïve patients, 
approximately 22% continued on thiopurines for longer than 
1 year. This suggests that the long-term benefits of sequential 
therapy with anti-TNF inhibitors followed by thiopurines in 
“anti-TNF failures” may equal the benefits of the combination 
of anti-TNF and thiopurines initiated simultaneously, as has 
recently been suggested by Lewis.23
We were surprised that 2,108 (74%) of all treatment fail-
ures were considered discontinuations of treatment. Accord-
ingly, we performed a series of analyses to further examine 
the discontinuers and exclude the possibility of misclas-
sification of either CD itself or medication discontinuation. 
Approximately, 57% of those that discontinued had claims 
with an ICD-9 diagnosis code for CD within 90 days of 6-MP/
AZA discontinuation, and 86% had CD claims at any point 
following 6-MP/AZA discontinuation, suggesting that these 
patients did, in fact, have CD and received ongoing care for 
their condition. In the 90 days following all maintenance 
treatment discontinuation, we found that 12% (n=259) had 
a claim for hospital admission, 5% (n=96) had a claim for a 
gastrointestinal-related surgery, and 0.3% (n=6) had a claim 
for cyclosporine, tacrolimus, or mycophenolate, which could 
be indicative of a maintenance treatment failure. However, in 
the same time period, we identified 674 individuals (32%) who 
had a prescription for 5-ASA or sulfasalazine, which would be 
consistent with a “step down” strategy due to improvements 
in disease course. As such, these data suggest that discontinu-
ers comprise a heterogeneous group of patients. Indeed, our 
findings of medication nonuse are consistent with the findings 
of a recent population-based study by Melesse et al,24 which 
used the University of Manitoba IBD Epidemiology Database 
linked to an outpatient prescription drug database. Research-
ers found that by the end of 5 years, only 46% of CD patients 
continued to use IBD medications.
Because our study relied upon administrative data, there 
are several limitations to consider when interpreting the results. 
One key issue discussed previously is the use of the outcome 
variable, continuation of 6-MP/AZA monotherapy, as a proxy 
variable for clinical effectiveness. Similarly, information on 
drug dosage was unavailable, and therefore, detection of 
underdosing, which may impact clinical effectiveness, could 
not be measured. Misclassification of the primary or second-
ary outcomes (augmentation, switch, and discontinuation) 
may have also occurred; however, medication dispensings 
are generally reliable administrative data because they require 
reimbursement by the health plans. We also recognize that our 
exploratory analysis of events suggestive of treatment intol-
erance and failure was limited by our reliance on algorithms 
using diagnosis and procedure codes and outpatient prescrip-
tion drug claims submitted to insurance companies that have 
not been validated. As additional clinically relevant events not 
contained within administrative data may have occurred, it is 
likely that we have underestimated such events but may have 
also overestimated events, such as colonoscopy, that may have 
been used for routine surveillance. Results from a large Spanish 
prospective cohort study of IBD patients by Chaparro et al25 
demonstrated that 25% of patients using thiopurines experi-
ence an adverse event during treatment, with nausea being the 
most common event (and one which is difficult to capture in 
claims data). Fraser et al13 reported similar findings of 28% 
of patients stopping AZA due to side effects, with nausea 
and vomiting as the main reason. Finally, our analysis relied 
upon information from commercially insured individuals and 
as such, patients who frequently change health plans would 
not have been captured, and the overall findings may not be 
generalizable to uninsured patients.
The primary strengths of this study were the incident user 
design and the broad diversity and large size of the study 
population. The CD cohort included initiators of 6-MP/AZA 
instead of prevalent users (“survivors of early 6-MP/AZA 
treatment”) so that we could identify early noncontinuation 
events and patient-level characteristics associated with failure 
to continue 6-MP/AZA monotherapy. As shown in Figure 2, 
the hazard of failure to continue treatment is highest in the 
early months following initiation and therefore, the incident 
user design is appropriate and necessary in this setting.18 
Additionally, the databases utilized for this study included 
diverse, commercially insured individuals diagnosed with 
CD, ranging in age from 3 to 100 years and residing in all 
regions of the USA. Furthermore, the study cohort had a wide 
distribution of comorbidity and health care utilization, which 
is often lacking in RCTs. Most of the prior observational 
studies examining the effectiveness of 6-MP/AZA in a 
routine care setting were small, single-center experiences. 
With 3,657 individuals included in this cohort and 2,845 
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Patterns of 6-MP/aZa maintenance treatment
experiencing a noncontinuation event, the sample size was 
sufficiently large to examine a wide range of patient-level 
predictors, while allowing for broad generalizability to the 
commercially insured CD population in the USA.
In summary, most patients who initiate on 6-MP/AZA 
monotherapy for CD do not continue on this treatment 
beyond 1 year, suggesting the limited long-term impact of 
this therapeutic strategy. In contrast to some adult and the 
pediatric RCTs, the lower real-world clinical effectiveness of 
6-MP/AZA monotherapy may be due to differences in a vari-
ety of factors, such as disease severity, patient demographics, 
comorbidity, adherence, and health care utilization.
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Table S1 administrative codes used to identify an initial 6-MP/
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Abbreviations: nDC, national Drug Code; hCPCs, healthcare Common 
Procedural Coding system; TnF, tumor necrosis factor.
Table S2 administrative codes used to identify possible indicators 
of intolerance or active disease
Source Description Codes
iCD-9 CM acute pancreatitis 577.0
iCD-9 CM liver toxicity 570, 790.4
iCD-9 CM low white blood cell count 288.5, 288.0
iCD-9 CM gi procedures 43200–43273, 44360–44397, 
45300–45392, 46600–46615
nDC Oral steroid prescription Codes
iCD-9 CM Crohn’s disease-related 
hospitalization
555.0, 555.1, 555.2, 555.9
Abbreviations: NDC, National Drug Code; ICD-9 CM, International Classification 
of Diseases, ninth revision codes; gi, gastrointestinal.
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